The city of Los Angeles, California, currently has 5 active clinical trials seeking participants for Crohn's Disease research studies.
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
Recruiting
Study participants will be screened during the platform study and randomly assigned to receive mirikizumab or another intervention. The purpose of the mirikizumab study is to evaluate efficacy, safety, tolerability, and how well mirikizumab absorbs into the body of pediatric participants with Crohn's disease. Study periods for the intervention-specific appendix (ISA) will be as follows: * A 12-week induction period * A maintenance period from Week 12 to Week 52, and * A safety follow-up period... Read More
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
04/17/2025
Locations: Cedars Sinai Medical Center, Los Angeles, California
Conditions: Crohn's Disease
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
Recruiting
The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with adalimumab or vedolizumab together with ustekinumab in adults with moderate to severe Crohn's Disease, and the effect of treatment with vedolizumab alone, after the dual targeted treatment. The study is conducted in two parts. In Part A, participants will receive the dual targeted treatment (vedolizumab together with either adalimumab or ustekinumab). In part B, participants will... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
04/01/2025
Locations: Cedars-Sinai Medical Center, Los Angeles, California
Conditions: Crohn's Disease
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
Recruiting
Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. The purpose of this study is to evaluate the efficacy and safety of TAK-279 versus placebo in participants with moderately to severely active Crohn's disease (CD). The main aim of this study is to learn if the 3 different doses of TAK-279 reduce bowel inflammation and ulcers in the bowel compared to the placebo after 12 weeks of treatment. Another aim is to compare any medical problems that... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/12/2025
Locations: GastroIntestinal BioSciences, Los Angeles, California
Conditions: Crohn's Disease
VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease
Recruiting
Transmural healing (TMH) is recognized as a potentially important measure of Crohn's disease (CD) activity but not a formal target. Observational studies suggest that TMH may be associated with better long-term outcomes. The study will evaluate TMH using noninvasive intestinal ultrasound (IUS), a patient-friendly technique that can be performed routinely in clinical practice. The aim of the study is to determine if treating to a target of corticosteroid-free (CS-free) IUS outcomes + clinical sym... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
02/20/2025
Locations: TLC Clinical Research Inc - Los Angeles, Los Angeles, California
Conditions: Moderately to Severely Active Crohn's Disease, Crohn Disease, Disease Crohn
A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
Recruiting
Vedolizumab is a medicine that helps to reduce inflammation and pain in the digestive system. In this study, children and teenagers with moderate to severe Crohn's disease will be treated with vedolizumab. The main aim of the study is to check if participants achieve remission after treatment with the vedolizumab. Remission means symptoms improve or disappear and an endoscopy shows no signs of inflammation. Participants will receive 3 infusions of vedolizumab over 6 weeks. Then, those who have... Read More
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
01/17/2025
Locations: Cedars Sinai Medical Center, Los Angeles, California
Conditions: Crohn's Disease (CD)